[Skip to Content]
[Skip to Content Landing]
October 18, 2000

Problems in Pharmacoeconomic Analyses—Reply

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(15):1922-1924. doi:10.1001/jama.284.15.1921

To the Editor: The pharmaceutical industry in Australia is certainly aware that pharmacoeconomic analyses are complex and difficult to evaluate, as stated in the article by Dr Hill and colleagues,1 but we disagree with its conclusions. It is also not obvious from the article that at least 2 of the authors were involved previously in more than 1 stage of the analysis of each submission. This brings their perspective into question.